Aktienanalyse zu Ainos Inc (AIMD)AIMDAinos Inc

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ainos Inc is not a good buy right now due to its extremely low RSI of 8.209, indicating oversold conditions, and a staggering 76.55% decline over the past year. The company's financials show a concerning trend with a gross margin of only 65.13% in Q2 2026, which is significantly lower than previous quarters, and a forward P/E ratio of 13.9082, suggesting potential overvaluation relative to its earnings outlook. The main risk is the company's current ratio of 0.13, indicating severe liquidity issues that could hinder its operations.